Monday, October 20, 2014

Cynapsus’ APL-130277 one of  “Top Ten Neurology Projects to Watch”

Cynapsus’ APL-130277 one of “Top Ten Neurology Projects to Watch”

October 14, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics’ (OTCQX:CYNAF; TSX-V:CTH) APL-130277 drug candidate for Parkinson’s disease has been recognized as one of the “Top Ten Neurology Projects to Watch” by a joint selection committee. The committee included Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain. Dr. Tracy is also the editor of the biotechnology publication, […]

Cynapsus names Dr. Thierry Bilbault as CSO, EVP

Cynapsus names Dr. Thierry Bilbault as CSO, EVP

October 7, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Dr. Thierry Bilbault, as CSO and EVP of chemistry, manufacturing and controls (CMC). In this role, Dr. Bilbault will lead the strategic CMC activities related to the company’s APL-130277 drug candidate, a convenient and easy to use sublingual thin filmstrip for the rescue of “off” motor symptoms of […]

Cynapsus appoints Ernst & Young as auditor

Cynapsus appoints Ernst & Young as auditor

September 19, 2014 by · Leave a Comment 

Tweet The board of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Ernst & Young as auditor for the company, effective immediately, replacing McGovern, Hurley, Cunningham, which resigned at the request of the company. In a statement, Cynapsus said there were no reservations in the former auditor’s reports in connection with the two most recently completed fiscal […]

Cynapsus to start Phase 2 trial of APL-130277


Cynapsus to start Phase 2 trial of APL-130277


July 17, 2014 by · Leave a Comment 

Tweet Following communication from the FDA, Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) announced that it will begin Phase 2 clinical studies for APL-130277 immediately. The CTH-105 study will be initiated according to a proposal submitted to the FDA under the company’s IND application. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug […]

Cynapsus gets additional grant from MJFF

Cynapsus gets additional grant from MJFF

July 8, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has been awarded a new grant of $500,000 from the Michael J. Fox Foundation (MJFF) for Parkinson’s research to support clinical studies to develop APL-130277, a sublingual thin film strip reformulation of apomorphine. This is the second grant that Cynapsus has received from the MJFF and will be used to fund […]

Three BT-featured CEOs sweep EY award finalist selections

Three BT-featured CEOs sweep EY award finalist selections

July 7, 2014 by · Leave a Comment 

Tweet All three finalists for the EY 2014 Ontario Entrepreneur of the Year award in the health sciences category have been featured in the past on BioTuesdays.com. They are Anthony Giovinazzo of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH), Tom Reeves of closely held Interface Biologics and Dr. Arun Menawat of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ). The Ontario winners will be announced […]

Cynapsus sees no irritation in APL-130277 animal test

Cynapsus sees no irritation in APL-130277 animal test

May 14, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) says there was no irritation observed when testing its APL-130277 sublingual apomorphine formulation in a buccal mucosal irritation model in hamsters, either macroscopically by a clinician or microscopically. “The data, coupled with our clinical results to date, continue to validate the design of our thin-film strip technology,” president and CEO […]

Cynapsus reports positive study data for APL-130277

Cynapsus reports positive study data for APL-130277

April 24, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive data from its recently completed CTH-104 healthy volunteer pilot study of a single, 25-milligram sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug in the U.S., Europe, Japan and other countries for the acute rescue of […]

Cynapsus files final short-form prospectus for offering

Cynapsus files final short-form prospectus for offering

April 9, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has filed a final short-form prospectus in British Columbia, Alberta and Ontario to sell a minimum of 23,076,923 units and a maximum of 38,461,538 units at a price of 65 cents each for gross proceeds of $15-million to $25-million. Each unit consists of one common share and one warrant. Each […]

Cynapsus files for financing

Cynapsus files for financing

March 31, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has filed a preliminary short-form prospectus with securities agencies in the provinces of British Columbia, Alberta and Ontario for a best-efforts offering of common shares and warrants for gross proceeds of $15-million to $25-million. The final pricing and the number of common shares and warrants to be sold will occur […]

Next Page »

Email Newsletters with Constant Contact
Google+